SNPX Synaptogenix, Inc: רווח למניה אחת ב-12 החודשים האחרונים

Synaptogenix, Inc. (SNPX) is accelerating the search for Alzheimer's treatments through automated bioinformatics. The EPS YoY TTM percentage change trend demonstrates profit dynamics, where the indicator value reaches 0.00. Patents and grants support the balance sheet for future cash flow, although speculative capital and strict FDA oversight create volatility within the closed Bryostatin ecosystem.

This indicator measures the dynamics of net income per share over the last twelve months relative to the previous year. By analyzing the annual growth rate of EPS TTM, an investor assesses capital generation efficiency and business scaling rates. The calculation is based on a comparison of final financial results, accounting for all corporate adjustments. For Synaptogenix, Inc. (SNPX), this metric reflects the preclinical development stage. A lack of resources for mergers and a dependence on grants make this figure an indicator of survivability until pharmaceutical partners are secured.